Castleman disease
ORPHA:160DiseaseNot applicableAll ages
Фенотипы (HPO)29
Очень частый (80–99%)1
HP:0002716Lymphadenopathy
Частый (30–79%)10
HP:0001824Weight loss
HP:0001903Anemia
HP:0002027Abdominal pain
HP:0002729Follicular hyperplasia
HP:0003565Elevated erythrocyte sedimentation rate
HP:0011227Elevated circulating C-reactive protein concentration
HP:0012378Fatigue
HP:0025142Constitutional symptom
HP:0030783Increased circulating interleukin 6 concentration
HP:0100721Mediastinal lymphadenopathy
Периодический (5–29%)9
HP:0000952Jaundice
HP:0002017Nausea and vomiting
HP:0003270Abdominal distention
HP:0008940Generalized lymphadenopathy
HP:0011024Abnormality of the gastrointestinal tract
HP:0012735Cough
HP:0025066Decreased mean corpuscular volume
HP:0030157Flank pain
HP:0031500Abdominal mass
Очень редкий (1–4%)9
HP:0000083Renal insufficiency
HP:0000790Hematuria
HP:0001723Restrictive cardiomyopathy
HP:0001873Thrombocytopenia
HP:0002094Dyspnea
HP:0005214Intestinal obstruction
HP:0006000Ureteral obstruction
HP:0011974Myelofibrosis
HP:0012050Anasarca
Эпидемиология2
| Тип оценки | Класс распространённости | Среднее (на 100к) | Регион | Квалификация |
|---|---|---|---|---|
| Point prevalence | Unknown | — | Worldwide | Class only |
| Annual incidence | 1-9 / 100 000 | — | United States | Class only |
Лекарства и терапия
Источник: Open Targets Platform (в реальном времени)
Клинические исследования
Источник: ClinicalTrials.gov (в реальном времени)